Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Diseases of the Liver and Gallbladder
Overview of Lipid Metabolism
Ultrasound II: Endoscopic Ultrasound and FibroScan
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 14, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Norio Akuta1,2, Tomomi Kogiso1,3, Kenichi Ikejima1
1Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease 2026 (3rd Edition)", The Japanese Society of Gastroenterology/The Japan Society of Hepatology, Tokyo, Japan.
Metabolic dysfunction-associated steatotic liver disease (MASLD) requires early risk stratification for advanced fibrosis. Guidelines recommend the FIB-4 index as a first-line tool, followed by elastography for higher-risk patients.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: